Start › Rak nerki (rak komórek nerkowych) › Nowy Jork › New York City
Badania kliniczne dla Rak nerki (rak komórek nerkowych) w mieście New York City, NY
27 badań dla Rak nerki (rak komórek nerkowych) szuka uczestników w ośrodkach w mieście New York City i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RekrutacjaFaza 1
- Research Site, New York
- Research Site, New York
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RekrutacjaFaza 1
- NEO-811 NYC Site, New York
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
RekrutacjaFaza 1/2
- Laura and Isaac Perlmutter Cancer Center ( Site 5016), New York
- Memorial Sloan Kettering Cancer Center ( Site 5002), New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RekrutacjaFaza 1
- Memorial Sloan Kettering Cancer Center, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekrutacjaFaza 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekrutacjaFaza 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekrutacjaBadanie obserwacyjne
- NYU Langone Medical Center, New York
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
RekrutacjaFaza 3
- Memorial Sloan Kettering Cancer Center ( Site 0126), New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
RekrutacjaFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RekrutacjaFaza 2
- Columbia University Irving Medical Center, New York
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RekrutacjaFaza 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Manhattan Eye Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
- i 1 więcej
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RekrutacjaFaza 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- i 1 więcej
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekrutacjaFaza 1
- Memorial Sloan Kettering Cancer Center, New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
RekrutacjaFaza 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RekrutacjaFaza 3
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- Manhattan Eye Ear and Throat Hospital, New York
- i 2 więcej
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Rekrutacja
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RekrutacjaFaza 1
- New York Cancer & Blood Specialists, New York
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RekrutacjaFaza 1
- Memorial Sloan Kettering Cancer Center, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekrutacjaFaza 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RekrutacjaFaza 1/2
- NYU Langone Health Perlmutter Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University - The Trustees of Columbia University in the City of New York, New York
- i 1 więcej
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
RekrutacjaFaza 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RekrutacjaFaza 1
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869, New York
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RekrutacjaFaza 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Decision Aid (DA) for Renal Patients
Rekrutacja
- NYU Langone Health, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekrutacjaFaza 1/2
- NYU Langone Health, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RekrutacjaFaza 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Badania dla Rak nerki (rak komórek nerkowych) w innych miastach
- Houston, TX35 badań
- Nashville, TN23 badań
- Dallas, TX23 badań
- St. Louis, MO23 badań
- Los Angeles, CA20 badań
- Boston, MA16 badań
- Baldwin Park, CA16 badań
- Pittsburgh, PA15 badań
- Philadelphia, PA15 badań
- Queens, NY15 badań
- Jacksonville, FL14 badań
- Rochester, MN14 badań
Inne badania w mieście New York City
- Rak piersi136 badań
- Niedrobnokomórkowy rak płuca121 badań
- Nowotwory (wszystkie typy)109 badań
- Rak prostaty103 badań
- Nowotwór przerzutowy93 badań
- Rak jelita grubego i odbytnicy78 badań
- Rak jajnika69 badań
- Rak płuc60 badań
- Szpiczak mnogi60 badań
- Rak trzustki60 badań
- Rak endometrium52 badań
- Ostra białaczka szpikowa51 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.